Physician profile
Patrick Deane Kent
NPI 1194250183
$2,436.56
in general payments reported to CMS, 2019-2025
18 companies · $645 in 2025
The $645 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.73 · 2021: $141 · 2022: $447 · 2023: $456 · 2024: $736 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,796 · Education: $39.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,795.83 |
| Education | $39.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $454.59 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $320.33 | 2021-2025 | Zerbaxa, Dificid, Recarbrio |
| Insmed, INC. | $311.50 | 2022-2025 | Arikayce, Brinsupri |
| Melinta Therapeutics, LLC | $216.26 | 2022-2024 | Rezzayo, Kimyrsa, Vabomere |
| Viiv Healthcare Company | $213.09 | 2023-2025 | Cabenuva, Dovato, Rukobia |
| Paratek Pharmaceuticals, INC. | $146.55 | 2021-2025 | Nuzyra |
| Aimmune Therapeutics, INC. | $141.85 | 2025 | Zenpep, Vowst |
| Pharming Healthcare, INC. | $122.93 | 2024 | |
| Astellas Pharma US INC | $114.10 | 2021-2024 | Cresemba |
| Abbvie INC. | $93.13 | 2021-2024 | |
| Ferring Pharmaceuticals INC. | $90.82 | 2022-2025 | Rebyota |
| Theratechnologies INC. | $46.46 | 2022-2025 | Trogarzo, Egrifta |
| Modernatx, INC. | $40.57 | 2024-2025 | Spikevax, Moderna Covid-19 Vaccine |
| La Jolla Pharmaceutical Company | $38.67 | 2022-2025 | Xacduro |
| Shionogi INC | $33.11 | 2024 | Fetroja |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $24.03 | 2025 | Vegzelma |
| Vbi Vaccine (Delaware) INC. | $15.84 | 2022 | |
| Edwards Lifesciences Corporation | $12.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Kent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.